Chase Investment Counsel Corp acquired a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) in the 2nd quarter, HoldingsChannel reports. The fund acquired 60,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,885,000.
Other large investors also recently made changes to their positions in the company. Smartleaf Asset Management LLC increased its holdings in Catalyst Pharmaceuticals by 55.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 630 shares in the last quarter. Clearstead Advisors LLC raised its position in Catalyst Pharmaceuticals by 192.9% in the fourth quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 1,167 shares during the period. Larson Financial Group LLC lifted its stake in shares of Catalyst Pharmaceuticals by 552.7% during the fourth quarter. Larson Financial Group LLC now owns 1,847 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 1,564 shares in the last quarter. Advisory Services Network LLC acquired a new position in shares of Catalyst Pharmaceuticals during the third quarter worth about $39,000. Finally, Quarry LP purchased a new stake in shares of Catalyst Pharmaceuticals in the third quarter worth about $40,000. Institutional investors and hedge funds own 79.22% of the company’s stock.
Analyst Upgrades and Downgrades
A number of research firms have recently issued reports on CPRX. Robert W. Baird lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 7th. Citigroup lowered Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $35.00 to $31.50 in a research report on Friday, May 8th. HC Wainwright cut Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $35.00 to $31.50 in a report on Thursday, May 28th. Weiss Ratings raised shares of Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, June 3rd. Finally, Wall Street Zen lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $32.00.
Catalyst Pharmaceuticals Price Performance
Shares of NASDAQ CPRX opened at $31.49 on Monday. The stock’s 50 day moving average price is $31.45 and its two-hundred day moving average price is $28.21. Catalyst Pharmaceuticals, Inc. has a 52-week low of $19.05 and a 52-week high of $32.56. The stock has a market capitalization of $3.86 billion, a P/E ratio of 18.10, a PEG ratio of 0.96 and a beta of 0.74.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.
The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).
Featured Articles
- Five stocks we like better than Catalyst Pharmaceuticals
- The Metals Company’s Big Bet Now Comes Down to a License
- OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings
- Meta and Tesla Are Rebounding From Oversold Levels—Now What?
- AMG’s Alternatives Boom Powers Record Growth
Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report).
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
